Video Experimental Relacionado
Updated: Jan 7, 2026

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.2K
¿Pueden los modelos in silico predecir el riesgo cardíaco inducido por medicamentos en poblaciones vulnerables?
Paula Dominguez-Gomez1,2, Pablo Gonzalez-Martin1,2, Laura Baldo-Canut1
1Elem Biotech, Pier 07, Via Laietana, 26, Barcelona, 08003, Spain.
Toxicology reports
|January 5, 2026
Resumen
No abstract available in PubMed .
Palabras clave:
Arritmia del ritmo cardíacoModelado cardíacoCardiomiopatíaSeguridad de las drogasProlongación del intervalo QDiferencias de géneroMás Videos Relacionados
Videos de Conceptos Relacionados
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Pharmacokinetic Models: Overview
1.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.8K

